// App-Quantinova.ai

: BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH B­CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP­ALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS

Researchers

Presenter

  • Nicola Goekbuget

Principal Investigators

  • Herv Dombret

  • Gerhard Zugmaier

  • Massimiliano Bonifacio

  • Carlos Graux

  • Christoph Faul

  • Max S. Topp

  • Monika Brggemann

  • Kate Taylor

  • Ralf Bargou

Medical Centers

  • Dept. of Medicine II,Goethe University Hospital,Frankfurt,Germany

  • Hematology,University Hôpital Saint­-Louis,Paris,France;Assistance Publique­-Hôpitaux de Paris,Paris,France

  • Amgen Research (Munich), Munich, Germany

  • Department of Medicine, Section of Hematology, Verona, Italy

  • Université Catholique de Louvain, CHU UCL Namur (Godinne),Yvoir,Belgium

  • University Hospital and Comprehensive Cancer Center Tübingen, Universitätsklinikum Tübingen,Tübingen,Germany

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

  • Klinik fur Innere Medizin I, Universitatsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

  • Amgen, Ltd., Uxbridge, United Kingdom

  • Comprehensive Cancer Center Mainfranken, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany

Locations

  • Germany

  • France

  • Italy

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01207388

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved